SLC5A2 and atherosclerosis: To date, significant CV benefits have been proven for several GLP-1ra and SGLT2-in drugs, and they are advised as a preferred treatment choice for patients with T2D and established ASCVD or those at an increased risk for ASCVD, independently of the glucose control level and the background use of metformin (the first-line medication).